Key facts
- Suzhou Heerkang Medical Technology’s last known valuation is $22.9M (Jan 2021).
- It has raised $760K; the latest was Early Stage VC in Nov 2025.
- Notable investors include Chengdu Bio-Town Investment, Hygeia Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Suzhou Heerkang Medical Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Suzhou Heerkang Medical Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Suzhou Heerkang Medical Technology
Developer of software platforms designed in the field of chronic diseases. The company's diabetes management system DMS and hypertension management system HMS are the first artificial intelligence diabetes and hypertension auxiliary diagnosis and treatment platforms in China, it has many collaborations with Chinese hospitals.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Ownership
- Privately Held (backing)
Suzhou Heerkang Medical Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Suzhou Heerkang Medical Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Suzhou Heerkang Medical Technology in its N-PORT filings yet. We sweep new filings monthly.